無菌注射剤CDMOの世界市場

無菌注射剤CDMOの世界市場は2030年までに63億米ドルに達する

2024年に41億米ドルと推定される無菌注射剤CDMOの世界市場は、2024年から2030年にかけてCAGR 7.4%で成長し、2030年には63億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである低分子は、CAGR 5.9%を記録し、分析期間終了時には37億米ドルに達すると予想されます。大型分子セグメントの成長率は、分析期間中CAGR 9.7%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 11.3％で成長予測

米国の無菌注射剤CDMO市場は、2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.1%と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の無菌注射剤CDMO市場- 主要動向と促進要因まとめ

なぜ無菌注射剤CDMOは現代のバイオ医薬品製造において重要なパートナーとして台頭しているのか？

無菌注射剤CDMO（開発・製造受託機関）は、製薬およびバイオテクノロジーのバリューチェーンにおいてますます戦略的な役割を果たすようになってきています。生物製剤、ワクチン、モノクローナル抗体、その他の非経口薬の台頭により、無菌製造能力は重要なボトルネックとなっています。従来の経口固形製剤とは異なり、無菌注射剤には精密さ、超清浄設備、堅牢な品質システムが要求され、これには多額の投資と技術的洞察力が必要とされます。その結果、大手製薬会社でさえ、実績のあるインフラ、規制上の認証、柔軟な製造能力を持つCDMOに無菌注射剤の製造をアウトソーシングしています。個別化医療、バイオシミラー、複雑な製剤に対する世界の需要の高まりは、ベンダーとしてだけでなく、市場投入までの時間を短縮し、リスクを低減し、規制の道を切り開くことのできる協力的なイノベーション・パートナーとしてのCDMOの重要性をさらに強めています。

高度な無菌技術と統合能力でCDMOはどのように進化しているのか？

無菌注射剤CDMO市場は急速に進化しており、注射剤開発と商業化の複雑化に対応するため、各社は最先端技術、自動化システム、統合ワークフローを採用しています。主な動向は、アイソレーターベースの充填ラインやRABS（アクセス制限バリアシステム）の広範な採用であり、これらは無菌処理中の汚染リスクを劇的に低減し、オペレーターの安全性を高める。多くのCDMOは、バイアル、プレフィルドシリンジ、カートリッジ、アンプルなどを同一施設内で処理する高速マルチフォーマット充填ラインで施設をアップグレードしています。シングルユースシステムの統合はもう一つの大きな進歩であり、洗浄バリデーションの負担を軽減し、特に生物製剤や多品種生産施設では生産の俊敏性を高めています。さらにCDMOは、初期段階の製剤や分析法の開発から、無菌充填仕上げ、凍結乾燥、ラベリング、シリアル化まで、ライフサイクル全般にわたるサービスを提供するようになってきています。eBatch記録、リアルタイム分析、自動品質管理システムなどのデジタル技術もまた、プロセスの一貫性、トレーサビリティ、規制遵守を向上させています。規制当局が世界的に無菌性保証基準を厳格化する中、CDMOは競争力を維持し、注射療法を開発する顧客の長期的パートナーとしての役割を果たすため、GMPのアップグレード、人材育成、データ整合性システムに積極的に投資しています。

市場の需要はどこで加速し、どのセグメントで拡大が加速しているか？

無菌注射剤CDMOサービスに対する需要は、地域や治療カテゴリーを問わず加速しており、既存の医薬品市場と新興医薬品市場の両方がその原動力となっています。北米と西欧は、イノベーション集約型のバイオテクノロジー拠点、確立された規制制度、製薬企業の成熟したアウトソーシング戦略に牽引され、CDMO契約額で引き続きリードしています。しかし、アジア太平洋、特にインド、中国、韓国は、バイオ製造能力の拡大、競争力のあるコスト構造、国際的な品質基準との整合性の高まりにより、急成長を遂げています。治療分野別では、ほとんどの最新がん治療薬が非経口的に投与され、高度に専門化された無菌処理を必要とすることから、がん領域が牽引役となっています。その他の主な成長分野には、自己免疫疾患や炎症性疾患、糖尿病などの代謝性疾患、中枢神経系疾患などがあり、これらの多くは長時間作用型の注射剤に依存しています。また、COVID-19や将来のパンデミック対策がワクチン製造の世界的拡大に拍車をかけており、ハイスループット充填・仕上げサービスに対する需要も高まっています。さらに、中小規模のバイオテクノロジー企業は、しばしば社内に能力を欠いているが、主要な顧客となっており、製造だけでなく、薬事サポート、臨床試験材料の生産、市場供給戦略についてもCDMOと契約しています。

世界の無菌注射剤CDMO市場の長期的成長の原動力は？

無菌注射剤CDMO市場の成長の原動力は、製薬業界の構造変化、治療方法の進化、世界の規制への期待、非経口薬開発の複雑化です。中心的な推進力は、自社製造が困難でコストのかかる生物製剤や特殊注射剤の台頭であり、深い技術的専門知識と無菌インフラを有するCDMOに対する持続的な需要を生み出しています。製薬会社やバイオテクノロジー企業の間で、よりスリムで資産の少ないビジネスモデルを目指す動向が強まっており、アウトソーシングは業務上の選択ではなく、戦略上必要なものとして強化されています。データの完全性、製品のトレーサビリティ、無菌精度の維持を求める規制上のプレッシャーも、スポンサーに世界市場でコンプライアンスを満たせるCDMOとの提携を促しています。特に新興感染症や生物学的製剤の上市に伴い、迅速なスケールアップ、柔軟なキャパシティ、世界サプライチェーンの回復力に対するニーズが高まっており、リスク分担やイノベーションを可能にするパートナーとしてのCDMOの役割は確固たるものとなっています。デジタル化、個別化医療、治験の分散化によって医薬品の情勢が大きく変化する中、スピード、拡張性、規制状況に精通した無菌注射剤CDMOは、世界ヘルスケアの提供に不可欠な存在であり続け、持続的かつ長期的な成長を遂げることができると思われます。

セグメント

分子タイプ（低分子、高分子）、製品（プレフィルドシリンジ、バイアル・アンプル、特殊注射剤、その他）、サービス（処方開発、分析・試験サービス、製造、包装、保管、その他）、投与経路（皮下、静脈内、筋肉内、その他）、治療領域（がん、循環器系疾患、中枢神経系疾患、感染症、筋骨格系疾患、ホルモン疾患、その他）

調査対象企業の例

• AbbVie Contract Manufacturing
• Aenova Group
• Ajinomoto Bio-Pharma Services
• Alcami Corporation
• Baxter International Inc.
• Bespak（Consort Medical）
• Boehringer Ingelheim
• Catalent, Inc.
• Cipla Inc.
• CordenPharma
• Delpharm
• Eurofins CDMO
• Famar Health Care Services
• Fresenius Kabi AG
• Grand River Aseptic Manufacturing
• Grifols S.A.
• Hikma Pharmaceuticals plc
• Jubilant HollisterStier
• Lonza Group
• NextPharma Technologies
• Patheon（Thermo Fisher）
• Pfizer CentreOne
• Recipharm AB
• Samsung Biologics
• Sandoz International GmbH
• Siegfried Holding AG
• Thermo Fisher Scientific
• Unither Pharmaceuticals
• Vetter Pharma
• WuXi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Sterile Injectables CDMO Market to Reach US$6.3 Billion by 2030

The global market for Sterile Injectables CDMO estimated at US$4.1 Billion in the year 2024, is expected to reach US$6.3 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Small Molecule, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Large Molecule segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 11.3% CAGR

The Sterile Injectables CDMO market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Sterile Injectables CDMO Market - Key Trends & Drivers Summarized

Why Are Sterile Injectables CDMOs Emerging as Critical Partners in Modern Biopharmaceutical Manufacturing?

Sterile injectables CDMOs (Contract Development and Manufacturing Organizations) are playing an increasingly strategic role in the pharmaceutical and biotech value chain, as companies seek specialized partners to manage the highly complex, capital-intensive, and strictly regulated production of injectable therapies. With the rise of biologics, vaccines, monoclonal antibodies, and other parenteral drugs, sterile manufacturing capabilities have become a critical bottleneck-one that CDMOs are uniquely equipped to solve through scale, expertise, and end-to-end service offerings. Unlike traditional oral solid dosage forms, sterile injectables demand precision, ultra-clean facilities, and robust quality systems, which require significant investment and technical acumen. As a result, even large pharmaceutical companies are outsourcing sterile injectable production to CDMOs with proven infrastructure, regulatory certifications, and flexible manufacturing capacity. The increased global demand for personalized medicine, biosimilars, and complex formulations is further reinforcing the importance of CDMOs, not only as vendors but as collaborative innovation partners capable of accelerating time-to-market, reducing risk, and navigating regulatory pathways.

How Are CDMOs Evolving with Advanced Aseptic Technologies and Integrated Capabilities?

The sterile injectables CDMO market is rapidly advancing, with players adopting cutting-edge technologies, automation systems, and integrated workflows to meet the growing complexity of injectable drug development and commercialization. A key trend is the widespread adoption of isolator-based filling lines and RABS (Restricted Access Barrier Systems), which dramatically reduce contamination risks and enhance operator safety during aseptic processing. Many CDMOs are upgrading their facilities with high-speed, multi-format filling lines that handle vials, prefilled syringes, cartridges, and ampoules-all within the same facility. Integration of single-use systems is another major advancement, reducing cleaning validation burdens and enhancing production agility, especially for biologics and multi-product facilities. Furthermore, CDMOs are increasingly providing full lifecycle services-from early-stage formulation and analytical method development to aseptic fill-finish, lyophilization, labeling, and serialization. Digital technologies such as eBatch records, real-time analytics, and automated quality control systems are also improving process consistency, traceability, and regulatory compliance. With regulators tightening sterility assurance standards globally, CDMOs are proactively investing in GMP upgrades, workforce training, and data integrity systems to stay competitive and serve as long-term partners to clients developing injectable therapies.

Where Is Market Demand Accelerating, and Which Segments Are Fueling Expansion?

Demand for sterile injectables CDMO services is accelerating across geographies and therapeutic categories, driven by both established and emerging pharmaceutical markets. North America and Western Europe continue to lead in terms of CDMO contract value, driven by innovation-intensive biotech hubs, well-established regulatory systems, and mature outsourcing strategies among pharmaceutical companies. However, Asia-Pacific-particularly India, China, and South Korea-is witnessing the fastest growth due to expanding biomanufacturing capacity, competitive cost structures, and growing alignment with international quality standards. In terms of therapeutic areas, oncology leads the charge, as most modern cancer therapies are delivered parenterally and require highly specialized sterile processing. Other key growth areas include autoimmune and inflammatory diseases, metabolic disorders like diabetes, and CNS-related conditions-many of which rely on long-acting injectable formulations. The global expansion of vaccine manufacturing, spurred by COVID-19 and future pandemic preparedness efforts, is also fueling demand for high-throughput fill-finish services. Additionally, small- and mid-sized biotech companies-often lacking in-house capabilities-are becoming major clients, engaging CDMOs for not only manufacturing but also regulatory support, clinical trial material production, and market supply strategies.

What’s Driving the Long-term Growth of the Sterile Injectables CDMO Market Globally?

The growth in the sterile injectables CDMO market is driven by structural shifts in the pharmaceutical industry, evolving therapeutic modalities, global regulatory expectations, and the increasing complexity of parenteral drug development. A core driver is the rise of biologics and specialty injectables, which are difficult and costly to manufacture in-house, creating sustained demand for CDMOs with deep technical expertise and sterile infrastructure. The trend toward leaner, asset-light business models among pharma and biotech companies is reinforcing outsourcing as a strategic necessity rather than an operational choice. Regulatory pressure to maintain data integrity, product traceability, and aseptic precision is also pushing sponsors to partner with CDMOs that can meet compliance across global markets. The growing need for rapid scale-up, flexible capacity, and global supply chain resilience-particularly in the context of emerging infectious diseases and biologic drug launches-has solidified the CDMO’s role as a risk-sharing, innovation-enabling partner. As digitalization, personalized medicine, and decentralized trials reshape the pharmaceutical landscape, sterile injectables CDMOs that offer speed, scalability, and regulatory sophistication will remain essential enablers of global healthcare delivery-positioned for sustained, long-term growth.

SCOPE OF STUDY:

The report analyzes the Sterile Injectables CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Molecule Type (Small Molecule, Large Molecule); Product (Pre-filled Syringes, Vials & Ampoules, Specialty Injectables, Others); Service (Formulation Development, Analytical & Testing Services, Manufacturing, Packaging, Storage, Others); Administration Route (Subcutaneous, Intravenous, Intramuscular, Others); Therapeutic Area (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• AbbVie Contract Manufacturing
• Aenova Group
• Ajinomoto Bio-Pharma Services
• Alcami Corporation
• Baxter International Inc.
• Bespak (Consort Medical)
• Boehringer Ingelheim
• Catalent, Inc.
• Cipla Inc.
• CordenPharma
• Delpharm
• Eurofins CDMO
• Famar Health Care Services
• Fresenius Kabi AG
• Grand River Aseptic Manufacturing
• Grifols S.A.
• Hikma Pharmaceuticals plc
• Jubilant HollisterStier
• Lonza Group
• NextPharma Technologies
• Patheon (Thermo Fisher)
• Pfizer CentreOne
• Recipharm AB
• Samsung Biologics
• Sandoz International GmbH
• Siegfried Holding AG
• Thermo Fisher Scientific
• Unither Pharmaceuticals
• Vetter Pharma
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Sterile Injectables CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Accelerating Shift Toward Outsourcing Throws the Spotlight on Sterile Injectables CDMOs as Critical Biopharma Partners
  • Surging Demand for Biologics and Specialty Injectables Spurs Growth in High-containment and Aseptic Manufacturing Capacity
  • Here's How Pharma's Focus on Speed-to-market Expands the Addressable Opportunity for Agile Sterile CDMOs
  • Increasing Complexity of Injectable Drug Products Strengthens the Business Case for Full-service Sterile Manufacturing Providers
  • Here's the Story: CDMOs Gain Strategic Value Amid Rising Demand for Vials, Pre-filled Syringes, and Cartridges
  • Growing Pipeline of Orphan and Personalized Therapies Fuels Need for Small-batch, High-precision Fill-finish Capabilities
  • Here's How Clinical Trial Acceleration and Early-phase Outsourcing Create Long-term Commercial Manufacturing Pipelines
  • Expansion of mRNA, ADCs, and Lyophilized Products Unlocks Demand for Specialized Sterile Injectable Capabilities
  • Global Biopharma's Push for Redundancy and Dual Sourcing Strategies Propels CDMO Network Expansion
  • Here's How Innovation in Closed Systems and Automation Enhances Sterility, Efficiency, and Workforce Safety
  • Emerging Markets and Local Fill-finish Initiatives Generate Growth Opportunities for Regional Sterile CDMO Facilities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sterile Injectables CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Sterile Injectables CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Sterile Injectables CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Packaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Storage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Storage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Storage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Formulation Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Formulation Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Formulation Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Analytical & Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Analytical & Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Analytical & Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Central Nervous System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Central Nervous System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Central Nervous System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Infectious Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Infectious Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Infectious Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Musculoskeletal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Musculoskeletal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Musculoskeletal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Hormonal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Hormonal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Hormonal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Pre-filled Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Pre-filled Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Pre-filled Syringes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 65: World Recent Past, Current & Future Analysis for Vials & Ampoules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: World Historic Review for Vials & Ampoules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: World 15-Year Perspective for Vials & Ampoules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 68: World Recent Past, Current & Future Analysis for Specialty Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: World Historic Review for Specialty Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: World 15-Year Perspective for Specialty Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 71: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 74: USA Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 77: USA Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: USA Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: USA 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 80: USA Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: USA Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: USA 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 83: USA Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: USA Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: USA 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 86: USA Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: USA Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: USA 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 89: Canada Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Canada Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Canada 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 92: Canada Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Canada Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Canada 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 95: Canada Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Canada Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Canada 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 98: Canada Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Canada Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Canada 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 101: Canada Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Canada Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Canada 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• JAPAN
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 104: Japan Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Japan Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Japan 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 107: Japan Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Japan Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Japan 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 110: Japan Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Japan Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Japan 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 113: Japan Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Japan Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Japan 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 116: Japan Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Japan Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Japan 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• CHINA
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 119: China Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: China Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: China 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 122: China Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: China Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: China 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 125: China Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: China Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: China 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 128: China Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: China Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: China 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 131: China Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: China Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: China 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• EUROPE
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Sterile Injectables CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Sterile Injectables CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 137: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Europe Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Europe 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 140: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Europe Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Europe 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 143: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Europe Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Europe 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 146: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Europe Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Europe 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 149: Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Europe Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Europe 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• FRANCE
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 152: France Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: France Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: France 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 155: France Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: France Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: France 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 158: France Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: France Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: France 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 161: France Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: France Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: France 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 164: France Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: France Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: France 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• GERMANY
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 167: Germany Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Germany Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Germany 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 170: Germany Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Germany Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Germany 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 173: Germany Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Germany Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Germany 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 176: Germany Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Germany Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Germany 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 179: Germany Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Germany Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Germany 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 182: Italy Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Italy Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Italy 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 185: Italy Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Italy Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Italy 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 188: Italy Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Italy Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Italy 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 191: Italy Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Italy Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Italy 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 194: Italy Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Italy Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Italy 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 197: UK Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UK Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: UK 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 200: UK Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UK Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: UK 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 203: UK Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UK Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UK 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 206: UK Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UK Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UK 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 209: UK Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: UK Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: UK 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 212: Spain Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Spain Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Spain 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 215: Spain Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Spain Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Spain 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 218: Spain Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Spain Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Spain 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 221: Spain Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Spain Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Spain 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 224: Spain Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Spain Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Spain 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 227: Russia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Russia Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Russia 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 230: Russia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Russia Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Russia 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 233: Russia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Russia Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Russia 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 236: Russia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Russia Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Russia 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 239: Russia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Russia Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Russia 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Europe Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Europe 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Europe Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Europe 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Europe Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Europe 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Europe Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Europe 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Europe Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Europe 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Sterile Injectables CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Asia-Pacific Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 263: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Asia-Pacific Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Asia-Pacific Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 269: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Asia-Pacific Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 272: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Asia-Pacific Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 275: Australia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Australia Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Australia 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 278: Australia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Australia Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Australia 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 281: Australia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Australia Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Australia 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 284: Australia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Australia Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Australia 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 287: Australia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Australia Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Australia 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• INDIA
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 290: India Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: India Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: India 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 293: India Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: India Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: India 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 296: India Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: India Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: India 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 299: India Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: India Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: India 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 302: India Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: India Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: India 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 305: South Korea Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: South Korea Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: South Korea 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 308: South Korea Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: South Korea Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: South Korea 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 311: South Korea Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: South Korea Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: South Korea 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 314: South Korea Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: South Korea Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: South Korea 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 317: South Korea Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: South Korea Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: South Korea 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Asia-Pacific Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Asia-Pacific Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Asia-Pacific Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Asia-Pacific Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 332: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Asia-Pacific Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Sterile Injectables CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Sterile Injectables CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 338: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Latin America Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Latin America 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 341: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Latin America Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Latin America 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 344: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Latin America Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Latin America 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 347: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Latin America Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Latin America 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 350: Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Latin America Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Latin America 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 353: Argentina Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Argentina Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Argentina 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 356: Argentina Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Argentina Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Argentina 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 359: Argentina Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Argentina Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Argentina 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 362: Argentina Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Argentina Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Argentina 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 365: Argentina Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Argentina Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Argentina 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 368: Brazil Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Brazil Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Brazil 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 371: Brazil Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Brazil Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Brazil 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 374: Brazil Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Brazil Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Brazil 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 377: Brazil Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Brazil Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Brazil 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 380: Brazil Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Brazil Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Brazil 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 383: Mexico Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Mexico Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Mexico 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 386: Mexico Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Mexico Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Mexico 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 389: Mexico Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Mexico Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Mexico 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 392: Mexico Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Mexico Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Mexico 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 395: Mexico Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Mexico Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Mexico 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Latin America Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Latin America 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Latin America Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Latin America 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Latin America Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Latin America 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 407: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Latin America Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Rest of Latin America 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 410: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Rest of Latin America Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Rest of Latin America 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Sterile Injectables CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Sterile Injectables CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 416: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Middle East Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Middle East 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 419: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Middle East Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Middle East 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 422: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Middle East Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Middle East 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 425: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Middle East Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 427: Middle East 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 428: Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Middle East Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 430: Middle East 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 431: Iran Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Iran Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 433: Iran 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 434: Iran Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Iran Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 436: Iran 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 437: Iran Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Iran Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 439: Iran 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 440: Iran Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Iran Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 442: Iran 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 443: Iran Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Iran Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 445: Iran 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 446: Israel Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Israel Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 448: Israel 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 449: Israel Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Israel Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 451: Israel 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 452: Israel Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Israel Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 454: Israel 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 455: Israel Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Israel Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 457: Israel 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 458: Israel Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Israel Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 460: Israel 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: Saudi Arabia Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 463: Saudi Arabia 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 464: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: Saudi Arabia Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 466: Saudi Arabia 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 467: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Saudi Arabia Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 469: Saudi Arabia 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 470: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: Saudi Arabia Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 472: Saudi Arabia 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 473: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: Saudi Arabia Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 475: Saudi Arabia 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 476: UAE Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: UAE Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 478: UAE 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 479: UAE Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: UAE Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 481: UAE 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 482: UAE Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: UAE Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 484: UAE 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 485: UAE Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: UAE Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 487: UAE 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 488: UAE Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: UAE Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 490: UAE 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Rest of Middle East Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 493: Rest of Middle East 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 494: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Rest of Middle East Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 496: Rest of Middle East 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 497: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Rest of Middle East Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 499: Rest of Middle East 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 500: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Rest of Middle East Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 502: Rest of Middle East 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 503: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Rest of Middle East Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 505: Rest of Middle East 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030
• AFRICA
  • Sterile Injectables CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 506: Africa Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 507: Africa Historic Review for Sterile Injectables CDMO by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 508: Africa 15-Year Perspective for Sterile Injectables CDMO by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
  • TABLE 509: Africa Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 510: Africa Historic Review for Sterile Injectables CDMO by Service - Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 511: Africa 15-Year Perspective for Sterile Injectables CDMO by Service - Percentage Breakdown of Value Sales for Packaging, Storage, Other Services, Formulation Development, Analytical & Testing Services and Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 512: Africa Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 513: Africa Historic Review for Sterile Injectables CDMO by Administration Route - Subcutaneous, Intravenous, Intramuscular and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 514: Africa 15-Year Perspective for Sterile Injectables CDMO by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intravenous, Intramuscular and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 515: Africa Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 516: Africa Historic Review for Sterile Injectables CDMO by Therapeutic Area - Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 517: Africa 15-Year Perspective for Sterile Injectables CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 518: Africa Recent Past, Current & Future Analysis for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 519: Africa Historic Review for Sterile Injectables CDMO by Product - Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 520: Africa 15-Year Perspective for Sterile Injectables CDMO by Product - Percentage Breakdown of Value Sales for Pre-filled Syringes, Vials & Ampoules, Specialty Injectables and Other Products for the Years 2015, 2025 & 2030

IV. COMPETITION